Welcome to GliaMed, Inc.
GliaMed is developing a small molecule approach to stem cell therapy.
Our drug candidates have the potential to enhance the regeneration of skin, cardiac muscle, cartilage, bone, brain and other tissues through the activation of reprogramming genes present in cells at the site of an acute trauma or injury, thus creating autologous stem cells that aid in the regeneration of tissue in situ.
Our lead candidate, GM1485, has been administered to more than 500 human subjects. We acquired this compound in 2007 and have repositioned it for regenerative medicine applications.